Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US BioDefense Inc.

www.usbiodefense.com

Latest From US BioDefense Inc.

US Capitol Capsule: Payers' Choice: Death Is Cheap; Drugs Add Costs

Former White House policy adviser Ezekiel Emanuel, who is now the vice provost and a professor at the University of Pennsylvania, famously wrote last year that he plans to stop all health care efforts to prolong his life once he reaches 75, contending the "manic desperation to endlessly extend life is misguided and potentially destructive."

Metabolic Disorders Infectious Diseases

What's Pharma Need To Get On Board With Biodefense?

It's been about a decade since Congress created the Biomedical Advance Research and Development Authority (BARADA), an agency aimed at accelerating the development of medical countermeasures against biological threats.

Infectious Diseases

AstraZeneca/BARDA In Antibiotics Deal; $170m Potential

AstraZeneca has entered into a public-private partnership with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to develop new antibacterials intended to address biothreat pathogens, in addition to antibiotic resistance, under a "portfolio" approach, which will allow the U.S. government funds to be steered away from a product that proves to be unsuccessful early on in the R&D process to other promising candidates.

US Capitol Capsule: Patent Challenge Landscape Shifting: Inter Partes Reviews Climb

While biopharmaceutical firms initially were slow to pursue inter partes reviews (IPRs) – trial proceedings intended to be a faster and more affordable way for third parties to challenge patents than going through the American court system – there's been a significant uptick in the past year in the number of petitions filed involving drug makers' patents, which has more than doubled from 4% the previous two years to 9%, said Washington lawyer Eleanor Yost, a partner in Goodwin Procter's intellectual property litigation group.

Infectious Diseases Cancer
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • US BioDefense Inc.
  • Senior Management
  • David Chin, CEO
  • Contact Info
  • US BioDefense Inc.
    Phone: (626) 961-0562
    13674 E. Valley Blvd.
    City of Industry , CA 91746
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register